Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: February 26, 2020
Expiration Date: February 26, 2021

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Risk stratification is critical when managing patients with MDS because guideline consensus treatment algorithms are distinguished by lower-risk disease and higher-risk disease. In this activity, Dr. Aziz Nazha explains next steps after risk stratifying your patient and the goal of therapy based on this assessment. He will also review novel formulations of hypomethylating agents (HMAs) in development and their potential use in MDS. Lastly, Dr. Nazha will cover key genetic mutations and the potential future investigations.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify studies examining new formulations of oral HMAs providing potential for new treatment alternatives
  • Outline genetic mutations in MDS driving the need for new therapeutic regimens
  • Describe practical, clinical, and patient education strategies that will support improved outcomes in patients with MDS


Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments – Aziz Nazha, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 26, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Aziz Nazha, MD
Assistant Professor, Lerner College of Medicine
Associate Staff, Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Dr. Aziz Nazha received his medical degree from Tishreen University in Syria, and continued his post-graduate training as a resident in internal medicine at Thomas Jefferson University Affiliated, Atlanticare Regional Medical Center. He also completed a leukemia fellowship at The University of Texas, MD Anderson Cancer Center, and a hematology and medical oncology fellowship at Cleveland Clinic, Taussig Cancer Institute. Dr. Nazha is an Assistant Professor at Lerner College of Medicine and an Associate Staff Member at Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Dr. Nazha is board certified by the American Board of Internal Medicine, American Board of Hematology, and the American Board of Medical Oncology. He holds memberships in the American Society of Clinical Oncology, American Society of Hematology, Society of Hematologic Oncology, American Medical Association, American College of Physicians, and the American Association of Cancer Research. Dr. Nazha is on the editorial boards of Annals of Hematology & Oncology, Annals of Clinical Case Reports, Journal of Blood Disorders and Therapy, Cancer Biology & Medicine, and Cancer Treatment and Research Communications. In addition, he is an ad hoc reviewer for the Journal of Clinical Oncology, Clinical Lymphoma, Myeloma & Leukemia, Journal of Graduate Medical Education, Journal of Blood Disorders and Therapy, Haematologica, Leukemia, Research, JAMA Oncology, Cancer Science, American Journal of Hematology, Journal of Leukocyte Biology, Leukemia & Lymphoma, and Leukemia. He has written and published more than 50 peer-reviewed articles and 70 abstracts.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-008-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Aziz Nazha has received honoraria related to formal advisory activities from MEI Pharma Inc., speakers’ bureau activities from Incyte Corporation and Novartis AG, as well as consultant fees from AbbVie Inc., Daiichi Sankyo, Inc., Karyopharm Therapeutics, and Takeda Oncology. He has received grant support related to research activities from Jazz Pharmaceuticals plc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.